Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Other Non-Current Assets (2017 - 2025)

Historic Other Non-Current Assets for Sutro Biopharma (STRO) over the last 9 years, with Q3 2025 value amounting to $858000.0.

  • Sutro Biopharma's Other Non-Current Assets rose 11.67% to $858000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $858000.0, marking a year-over-year increase of 11.67%. This contributed to the annual value of $7.2 million for FY2024, which is 10106.53% up from last year.
  • Sutro Biopharma's Other Non-Current Assets amounted to $858000.0 in Q3 2025, which was up 11.67% from $858000.0 recorded in Q2 2025.
  • Sutro Biopharma's 5-year Other Non-Current Assets high stood at $7.2 million for Q4 2024, and its period low was $857000.0 during Q1 2024.
  • Over the past 5 years, Sutro Biopharma's median Other Non-Current Assets value was $872000.0 (recorded in 2021), while the average stood at $1.3 million.
  • Per our database at Business Quant, Sutro Biopharma's Other Non-Current Assets skyrocketed by 571333.33% in 2021 and then tumbled by 172.02% in 2024.
  • Quarter analysis of 5 years shows Sutro Biopharma's Other Non-Current Assets stood at $872000.0 in 2021, then changed by 0.0% to $872000.0 in 2022, then skyrocketed by 309.06% to $3.6 million in 2023, then skyrocketed by 101.07% to $7.2 million in 2024, then crashed by 88.04% to $858000.0 in 2025.
  • Its last three reported values are $858000.0 in Q3 2025, $858000.0 for Q2 2025, and $858000.0 during Q1 2025.